Deep Value: cash covers more than 100% of the stock price

This company holds roughly $176M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

OnKure Therapeutics

OKUR

Biotechnology · Healthcare

Price

$3.94

+0.01 (+0.25%)

Market Cap

$159.6M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+644.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.8M (2021) → 13.5M (2025)

Winston Score History

The full picture

OnKure Therapeutics is a small biotechnology company focused on developing drugs to treat cancer. It works on targeted therapies, meaning medicines designed to attack specific proteins that help cancer cells grow. The company is in the research and development stage, so it does not yet sell any approved products to patients.

OnKure does not currently generate revenue from product sales, which is typical for early-stage biotech companies. It is based in the United States and funds its operations through investor capital and potentially research grants or partnerships. The company's main risk is that drug development is expensive, takes many years, and most experimental drugs fail before reaching patients — meaning OnKure must continue raising money while its pipeline advances through clinical trials.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+72.8% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$48M/ year

↑ Rising (+10% vs prior year)

R&D investment increasing — building for the future

Insider Activity

34.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~4 years

$176M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$176M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-36.1%

Weak — -36.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial